Most nootropics sharpen the brain you already have. Dihexa is in a different category. It is one of the only compounds in the world shown to actually build new synapses.
🔑 Key Takeaways
- Dihexa (code name PNB-0408) is a six-amino-acid peptide derivative of angiotensin IV, developed by Dr. Joseph Harding's lab at Washington State University around 2011
- It is unusual among peptides in two ways: it is orally bioavailable, and it crosses the blood-brain barrier. Most peptides cannot do either
- Its primary mechanism is activating the hepatocyte growth factor (HGF) / c-Met receptor pathway in the brain, which drives synaptogenesis (formation of new synaptic connections between neurons)
- In early animal studies, dihexa reversed cognitive deficits in Alzheimer's disease models and showed potency orders of magnitude higher than brain-derived neurotrophic factor (BDNF) in synaptogenesis assays
- No human clinical trials have been completed. All efficacy and safety claims rest on animal data and a small anecdotal community record
- Typical community protocols use 2 to 5 mg subcutaneously or 8 to 45 mg orally daily, cycled 4 to 6 weeks on with 2 to 4 weeks off
- Reported side effects are mild and mostly cognitive overstimulation (insomnia, headaches, restlessness, mild anxiety)
- The main theoretical safety concern is that c-Met is an oncogene. No confirmed cancer cases have been reported, but people with active cancer or significant cancer risk should avoid it
This page is a full reference on dihexa peptide: what it is, where it came from, how it works at the receptor level, every documented benefit, the real-world dosing ranges, side effects, contraindications, stacks, legal status, and what the research actually shows (and does not show) in 2026.
What Is Dihexa?
A small peptide with an unusually big effect.
Dihexa is a synthetic six-amino-acid peptide built as an analog of angiotensin IV (Ang IV), a fragment of the angiotensin hormone system. The full IUPAC name is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Its code name in early research literature is PNB-0408. The molecular formula is C27H44N4O5 and the molecular weight is 504.67 g/mol.
Dihexa at a Glance
- Chemical name: N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide
- Code name: PNB-0408
- CAS: 1401708-83-5
- Molecular formula: C27H44N4O5
- Molecular weight: 504.67 g/mol
- Derived from: Angiotensin IV hexapeptide
- Developed by: Dr. Joseph Harding and team, Washington State University (2011)
- Primary mechanism: HGF / c-Met receptor pathway activation, driving synaptogenesis
- Delivery routes: Oral (unusual for peptides) and subcutaneous injection
- Research stage: Early-stage animal studies only, no completed human trials
Two things make dihexa stand out from every other peptide in the nootropic category. First, it survives digestion and is orally bioavailable, which most peptides are not because stomach enzymes destroy them. Second, it is small and lipophilic enough to cross the blood-brain barrier, so it reaches its site of action in the central nervous system. The combination is rare: most compounds with cognitive activity either need to be injected or cannot reach the brain effectively.
How Dihexa Works
The HGF/c-Met pathway is the key.
Dihexa binds hepatocyte growth factor (HGF) and amplifies its signaling through the c-Met receptor. HGF/c-Met activation in the central nervous system triggers a cascade that drives new synapse formation (synaptogenesis), strengthens existing synaptic connections (synaptic plasticity), and supports dendritic spine growth. Synapses are the connection points between neurons. Building more of them, and strengthening the ones you already have, is the structural basis of learning and memory.
In the original discovery paper by Benoist and colleagues at Washington State University, dihexa was reported to increase synaptic density in hippocampal neurons at picomolar concentrations. The comparison point that made headlines was that dihexa produced synaptogenic activity in these assays at concentrations roughly seven orders of magnitude lower than BDNF, the canonical synaptogenesis-promoting neurotrophic factor. The widely-repeated "10 million times more potent than BDNF" claim comes from this dose-response relationship. It is accurate in the specific context of those in vitro assays, but does not translate linearly to a 10-million-times effect in a living brain.
Why the HGF/c-Met pathway matters for cognition
The HGF/c-Met system has three relevant effects for the brain:
- Synaptogenesis: Activates signals that build new synaptic connections, the structural foundation of new memory formation and learning
- Neuronal survival: Supports survival signaling pathways that protect existing neurons against stress, ischemia, and neurodegenerative damage
- Dendritic spine maturation: Promotes the structural maturation of dendritic spines, which strengthens communication between neurons
Angiotensin IV (the natural precursor dihexa is modeled on) binds to the AT4 receptor, now known to be the IRAP enzyme (insulin-regulated aminopeptidase). For years, researchers believed AT4 was the target. Later work clarified that dihexa's cognitive effect is driven through HGF/c-Met rather than directly through IRAP, though the IRAP relationship remains relevant.
Dihexa Benefits
Every documented effect and the research behind it.
Memory and learning enhancement
The core claim. In aged Alzheimer's disease animal models, dihexa administration reversed deficits in spatial memory tasks like the Morris water maze. The effect size in these animal studies was substantial enough that researchers described dihexa as a potential cognitive-enhancing and Alzheimer's therapeutic candidate. Users report improved short-term recall, faster learning of new material, and clearer "connection-making" between ideas within 1 to 4 weeks of consistent use.
Synaptogenesis and neuroplasticity
Unlike most cognitive enhancers that work through neurotransmitter modulation (dopamine, acetylcholine, norepinephrine), dihexa operates at a structural level by forming new synapses. This is the more durable category of cognitive change. Neurotransmitter modulators produce effects that end when the drug clears. Structural changes to synaptic architecture can persist beyond the drug's clearance window.
Neurogenesis support
HGF/c-Met signaling also supports neurogenesis, the formation of new neurons in areas of the brain that retain that capability (primarily the hippocampus in adults). Animal research has shown dihexa administration associated with increased neurogenesis markers, though direct measurement of new neuron formation in living humans is difficult.
Alzheimer's disease research
Dihexa's original development target was Alzheimer's. The compound reverses cognitive deficits in animal models of Alzheimer's by rebuilding synaptic connections lost to the disease. Whether this translates to human Alzheimer's outcomes is unknown because no human Alzheimer's trial has been completed. The animal data is strong enough that it remains an active research interest.
Parkinson's disease investigation
Dihexa has been explored in Parkinson's animal models for potential neuroprotection and dopaminergic support. The evidence here is thinner than for Alzheimer's, and no clinical trials have tested it in Parkinson's patients.
Traumatic brain injury recovery
The synaptogenic mechanism makes dihexa a theoretically attractive compound for post-TBI cognitive recovery. Animal studies in TBI models have shown improved recovery trajectories, but again, no human data exists.
Mental clarity and focus
Anecdotal. Community users consistently report improved mental clarity, sharper thinking, and faster recall within weeks of consistent use. These reports are unvalidated but remarkably consistent across community sources. The mechanism is plausibly connected to the synaptogenic and neuroplastic effects, but these anecdotal reports have not been tested in controlled trials.
Dihexa Dosage
Two routes, wide ranges, all community-derived.
All dosing recommendations for dihexa are community-derived from a combination of extrapolation from animal studies, user reports, and the practical bioavailability of the compound. No FDA-approved dose exists because there is no FDA approval.
Oral dihexa dosage
- Starting dose: 8 to 15 mg once daily
- Standard dose: 15 to 25 mg once daily
- Upper range: 30 to 45 mg once daily (higher end of community protocols)
- Timing: Taken in the morning with food to reduce insomnia risk
- Vehicle: Often dissolved in DMSO, MCT oil, or olive oil for improved absorption
The wide dose range reflects the uncertainty. Oral bioavailability is not precisely characterized in humans, so ranges span roughly 3x. Most users land around 20 to 25 mg as a working dose.
Subcutaneous dihexa dosage
- Starting dose: 2 mg once daily
- Standard dose: 3 to 5 mg once daily
- Upper range: 7 mg once daily (less commonly used)
- Timing: Morning injection, subcutaneous into abdomen, thigh, or upper arm
- Reconstitution: A 15 mg vial with 1.5 mL bacteriostatic water gives 10 mg/mL. A 3 mg dose is 30 units on a standard U-100 insulin syringe. Use our reconstitution calculator for other vial sizes
Subcutaneous dosing is lower because bioavailability is higher and more predictable than oral. Some users prefer injection for consistency; others prefer oral for convenience.
Cycling protocol
- Standard cycle: 4 to 6 weeks on, 2 to 4 weeks off
- Rationale: Prevents receptor desensitization and allows the nervous system to integrate the new synaptic architecture without continuous growth pressure
- Long-term protocol: Some users cycle 2 months on, 1 month off indefinitely. Others take extended breaks (3 to 6 months off) between multi-week uses
- No permanent use recommended: Given the absence of long-term human safety data and the c-Met pathway's relationship with cancer biology, continuous daily use is not advised
Dihexa Side Effects
Mild in practice. Theoretical concerns exist.
No controlled human safety study has been conducted, so all side effect data is either animal-based or anecdotal community reports. Short-duration animal studies have not shown acute toxicity, but long-term human effects remain unknown.
| Side effect | Frequency | Context |
|---|---|---|
| Insomnia or disrupted sleep | Common | Especially with evening dosing. Move dose to morning |
| Mild headaches | Occasional | Usually first week. Resolves with hydration or dose reduction |
| Restlessness or mild anxiety | Occasional | Cognitive overstimulation effect. Fades with adaptation |
| Increased mental "noise" | Uncommon | Racing thoughts, difficulty winding down |
| Injection site reactions | Uncommon | Subcut route only. Redness or mild soreness |
| Mild stomach upset | Uncommon | Oral route only. Take with food |
Theoretical Safety Concerns
- c-Met oncogene activity: c-Met is a known oncogene implicated in several cancer types (hepatocellular, gastric, renal, lung). Activating it pharmacologically, even through an HGF-potentiating mechanism, creates a theoretical concern for promoting tumor growth in people with undetected or active cancer. No case reports have linked dihexa to new cancer development, but the mechanism warrants caution
- No long-term human safety data: Animal studies are short-duration. Chronic-use effects in humans are unknown
- No pregnancy or pediatric data: Avoid in both populations
- Interaction with cancer therapy: c-Met is the target of several cancer drugs. Dihexa could theoretically interfere with c-Met inhibitor therapy
Who Should Not Use Dihexa
Do NOT Use Dihexa If You Have:
- Active cancer of any type (c-Met oncogene concern)
- Personal history of HGF-pathway-related cancers (hepatocellular, gastric, renal, lung)
- Currently taking c-Met inhibitors or other targeted cancer therapies
- Pregnancy or active breastfeeding (no safety data)
- Age under 18 (developing brain, no pediatric data)
- Known hypersensitivity to dihexa or any component of the formulation
People with a strong family history of HGF-pathway cancers should also think carefully before starting dihexa and discuss with a physician familiar with the compound.
Dihexa Stacks and Combinations
Dihexa pairs cleanly with most nootropic peptides and several adjacent compounds.
- Dihexa + Semax: Semax modulates BDNF and neurotransmitter systems; dihexa drives structural synaptogenesis. The two operate on different mechanisms and pair well for cognitive enhancement.
- Dihexa + Selank: Dihexa for cognition and synaptogenesis, Selank for calm focus and anxiolysis. Good combination for high-stress cognitive demands.
- Dihexa + NAD+ (NMN or NR 250 to 500 mg daily): Cellular energy plus synaptogenesis. Some users report stronger subjective effect.
- Dihexa + Lion's Mane (500 to 1,000 mg daily): Lion's Mane supports NGF; dihexa supports HGF/c-Met. Overlapping but distinct neurotrophic pathways.
- Dihexa + Methylene Blue (low dose): Electron transport chain support on top of synaptic structure support. More speculative.
- Dihexa + PE 22-28: Both nootropic peptides. Synergy reported anecdotally.
Avoid stacking dihexa with any c-Met inhibitor or HGF-pathway-modifying drug. The most common mistake is layering too many compounds simultaneously, which makes it impossible to attribute effects and side effects to any one of them. Start dihexa alone, establish a baseline, and add other compounds one at a time.
Dihexa vs Other Cognitive Peptides
| Compound | Primary mechanism | Best for | Evidence |
|---|---|---|---|
| Dihexa | HGF/c-Met activation, synaptogenesis | Memory, learning, structural neuroplasticity | Strong animal data, no human trials |
| Semax | BDNF upregulation, neurotransmitter modulation | Focus, memory, neuroprotection | Russian clinical use since 1990s |
| Selank | GABAergic modulation, neuropeptide Y | Anxiolysis with cognitive preservation | Russian clinical use |
| Cerebrolysin | Mixed neuropeptide cocktail, multiple pathways | Post-stroke, TBI, dementia | Clinical use in Europe and Asia |
| Noopept | Cholinergic, NGF, BDNF modulation | Memory, mild nootropic lift | Russian clinical use, limited Western trials |
| Lion's Mane (hericenones/erinacines) | NGF stimulation | Nerve regeneration, mild cognitive support | Limited human data |
Dihexa's distinguishing feature is structural synaptogenesis. Most other nootropics work by modulating neurotransmitter signaling or by protecting existing neurons. Dihexa builds new connections. That makes it a strong pairing with compounds that modulate function (Semax, Noopept) rather than a replacement for them.
Dihexa Legal Status and the April 22, 2026 FDA Category 2 Update
The regulatory picture just shifted.
On April 15, 2026, the FDA published its 503A Categories Update removing 12 peptides from Category 2, the "significant safety concerns" bucket that compounding pharmacies had been using as legal grounds to refuse prescriptions. The change took effect April 22, 2026. Dihexa acetate was one of the 12. It now sits with LL-37, GHK-Cu, PEG-MGF, and Melanotan II on the list of peptides scheduled for a formal Pharmacy Compounding Advisory Committee (PCAC) review before the end of February 2027.
What this actually means:
- Not approval. Removal from Category 2 is not FDA approval. Dihexa is still not an approved drug for any indication.
- Legal scaffolding for refusal is gone. Before April 22, pharmacies could cite Category 2 status as an explicit reason to decline dihexa prescriptions. That specific citation no longer applies.
- Practical access did not change overnight. Most compounding pharmacies will still wait for the PCAC vote in 2027 before actually compounding dihexa. Telehealth providers will not prescribe it. No licensed clinician will write for it until PCAC decides.
- Research-use sales continue. Dihexa is still sold as lab-use material in the US and internationally, the same regulatory category BPC-157 and TB-500 occupied before their own Category 2 removal.
Outside the US, regulatory status varies. Some countries mirror US treatment; others have stricter research-chemical restrictions. Buyers should verify local status before ordering across borders.
Research Credibility: What You Should Know About the Athira Pharma Settlement
This part is usually left out of dihexa coverage, and it should not be.
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was developed at Washington State University in the lab of Joseph Harding. Athira Pharma, originally M3 Biotechnology, was founded in 2011 by PhD student Leen Kawas to commercialize dihexa and a related compound called ATH-1017, later named fosgonimeton. Kawas served as CEO until 2021, when the Athira board placed her on leave after allegations that she had manipulated images in her doctoral dissertation and in published research papers.
Those papers formed the foundational preclinical case for dihexa's nootropic claims, including the widely-cited "7 orders of magnitude more potent than BDNF" synaptogenesis numbers that made the compound famous online. Four papers in the Journal of Pharmacology and Experimental Therapeutics received formal expressions of concern from the journal.
On January 6, 2025, the Department of Justice announced that Athira Pharma agreed to pay $4,068,698 to settle False Claims Act allegations. The settlement covered conduct between January 1, 2016 and June 20, 2021. Athira had failed to disclose the research misconduct allegations to the NIH in grant applications that referenced the manipulated papers, including a 2019 NIH-funded grant. The whistleblower, Andrew P. Mallon, received $203,434 for bringing the case.
What this means for people evaluating dihexa:
- The mechanism is still broadly supported. HGF/c-Met activation, the pathway dihexa works through, has been corroborated by other labs independent of the Harding group's flagged papers. The basic biology is not in dispute.
- The specific dramatic claims are in question. The "7x BDNF" synaptogenesis numbers trace back to papers now under formal expressions of concern. Independent replication of those specific potency figures is thin.
- Zero human clinical trials of dihexa exist. Every cognitive claim about dihexa in humans is anecdotal or extrapolated from animal work. Fosgonimeton, the related Athira compound that did enter clinical trials, failed its Phase 2 Alzheimer's study (LIFT-AD) for efficacy in 2023, and Athira discontinued its development.
- Community protocols continue. Despite the credibility issues, online nootropic communities continue to report subjective cognitive effects from subcutaneous dihexa at 5-10 mg per dose. Whether these effects are dihexa-specific, placebo, or something else has not been tested in a controlled human study.
None of this makes dihexa definitively ineffective. It does mean the evidence base is weaker than the marketing implies, and that anyone buying it should go in with realistic expectations rather than the "7x BDNF miracle peptide" framing that dominates older articles.
[Image #1]
Dihexa Results Timeline
Steady, not dramatic.
- Week 1: Most users report no noticeable effect. Some report subtle clarity or focus.
- Weeks 2-3: Clearer mental processing, faster word retrieval, easier learning of new material. Some users report more vivid dreams.
- Weeks 4-6: Peak subjective effect. Memory recall, learning speed, and connection-making all improved. Best suited for phases where new learning is happening.
- After stopping (cycle-off phase): Effects persist partially because synaptic architecture changes take time to remodel. Not a clean on/off compound like caffeine.
- Multi-cycle use: Some users report compounding effects over multiple cycles, consistent with structural neuroplasticity changes accumulating over time.
Dihexa is not a stimulant. There is no "wake up and feel the nootropic" effect. Expect gradual, durable change that reveals itself in how easily new information sticks rather than in how sharp a single day feels.
Where to Buy Dihexa
Source quality matters, and the gray-zone status of dihexa means quality varies wildly across suppliers.
What to look for:
- ≥99% purity verified by independent HPLC and mass spectrometry
- Third-party COA (Certificate of Analysis) available for each batch
- US-based manufacturing with proper cold-chain handling
- Lyophilized vials for injectable form, sealed capsules or compounded liquid for oral
- Clear lot numbers and batch documentation
Avoid any source that cannot provide independent lab verification, sells "bulk powder" without batch testing, or ships internationally from unknown manufacturing sources. For a broader breakdown on vendor vetting, see our best legit peptide vendors guide.